Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine

Decitabine improves overall survival in myelodysplastic syndromes (MDS). This retrospective analysis of 2 decitabine studies (N=183) compared patients with baseline marrow blasts ≥20% (RAEB-t group, acute myeloid leukemia [AML] by WHO criteria) and <20% (MDS group). There was no significant diffe...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jabbour, Elias, Kantarjian, Hagop, O’Brien, Susan, Kadia, Tapan, Malik, Asifa, Welch, Mary-Alma, Teng, Angela, Cortes, Jorge, Ravandi, Farhad, Garcia-Manero, Guillermo
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4120256/
https://ncbi.nlm.nih.gov/pubmed/23790798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.05.004
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky